NCT03613701

Brief Summary

Moyamoya disease is a chronic cerebrovascular disease，The typical pathological manifestations are the stenosis or occlusion of the distal internal carotid artery and/or middle cerebral artery, and the proximal anterior cerebral artery. Meanwhile, the abnormal vascular net, which is the smokey vessel, occurs at the bottom of the brain. Currently the pathogenesis of this disease is unknown. Limited studies have reported the expression of endothelial progenitor cells (EPCs) in moyamoya disease, but the results were inconsistent. Some investigators believe that the number of EPCs in peripheral blood of patients with moyamoya disease is increased, while others believe that the number of EPCs in peripheral blood of moyamoya patients is reduced. Therefore, the investigators need to find a more accurate detection method to confirm the growth of EPC in patients with moyamoya disease. At the same time, whether there is endothelial injury in patients with smoke disease, and the expression of endothelial cells (CEC) in patients with smoke disease, there is no research on this aspect at home and abroad.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
120

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Sep 2017

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2017

Completed
11 months until next milestone

First Submitted

Initial submission to the registry

July 29, 2018

Completed
5 days until next milestone

First Posted

Study publicly available on registry

August 3, 2018

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2019

Completed
1.3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2020

Completed
Last Updated

January 31, 2019

Status Verified

January 1, 2019

Enrollment Period

2 years

First QC Date

July 29, 2018

Last Update Submit

January 29, 2019

Conditions

Moyamoya Disease

Keywords

Moyamoya diseaseEndothelial progenitor cellsrevascularization

Outcome Measures

Primary Outcomes (1)

  • Expression of endothelial progenitor cells and endothelial cells in peripheral blood

    Expression of endothelial progenitor cells and endothelial cells in peripheral

    2017.9-2018.8

Study Arms (1)

Moyamoya disease patients

Moyamoya disease patients/Healthy volunteers

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

Health volunteers' inclusion criteria: 1. Age between 18-60; 2. Male or female; Exclusion criteria: Exclude the volunteers with history of cerebrovascular disease and heart disease.

You may qualify if:

  • Whole-brain vessels angiography or magnetic resonance arteriography (MRA) has the following manifestations: stenosis or occlusion of terminal internal carotid artery or the anterior cerebral artery and/or initiating middle cerebral artery; In the arterial phase, the abnormal smokey vascular net near the occlusive or stenosis lesion can be seen.
  • For patients with stable stroke, there was no acute or subacute cerebral infarction or cerebral hemorrhage, and at least 3 months before the last cerebral infarction or cerebral hemorrhage events.

You may not qualify if:

  • Exclude atherosclerosis, autoimmune diseases, meningitis, intracranial tumors, multiple neurofibromatosis, Down syndrome, craniocerebral trauma, radiation injury, and other underlying diseases that may cause smoke.
  • Acute or subacute cerebral infarction or cerebral hemorrhage were excluded.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The 307th Hospital of Military Chinese People's Liberation Army

Beijing, Beijing Municipality, 100071, China

RECRUITING

Related Publications (2)

  • Gao G, Liu SM, Hao FB, Wang MJ, Wang QN, Yang RM, Guo QB, Wang XP, Li JJ, Han C, Duan L, Zhang JN. Treatment for moyamoya disease with hyperhomocysteinemia. J Cereb Blood Flow Metab. 2025 Aug;45(8):1469-1478. doi: 10.1177/0271678X251325676. Epub 2025 Mar 13.

    PMID: 40079509DERIVED

  • Gao G, Hao FB, Wang QN, Wang XP, Liu SM, Wang MJ, Guo QB, Li JJ, Bao XY, Han C, Duan L. Surgical outcomes following encephaloduroarteriosynangiosis in moyamoya disease associated with hyperhomocysteinemia. Brain Behav. 2023 Aug;13(8):e3093. doi: 10.1002/brb3.3093. Epub 2023 Jun 29.

    PMID: 37386744DERIVED

MeSH Terms

Conditions

Moyamoya Disease

Condition Hierarchy (Ancestors)

Carotid Artery DiseasesCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesCerebral Arterial DiseasesIntracranial Arterial DiseasesArterial Occlusive DiseasesVascular DiseasesCardiovascular Diseases

Study Officials

  • Lian Duan, Chief

    The 307th Hospital of Military Chinese People's Liberation Army

    STUDY CHAIR

Central Study Contacts

Lian Duan, Chief

CONTACT

0086-10-66947156keyan307@163.com

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Target Duration
6 Months
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 29, 2018

First Posted

August 3, 2018

Study Start

September 1, 2017

Primary Completion

September 1, 2019

Study Completion

December 1, 2020

Last Updated

January 31, 2019

Record last verified: 2019-01

Data Sharing

IPD Sharing
Will not share

Locations

CN(1)